Yuka Muramatsu-Maekawa1, Kyojiro Kawakami2, Yasunori Fujita3, Manabu Takai1, Daiki Kato1, Keita Nakane1, Taku Kato4, Tomohiro Tsuchiya1, Takuya Koie1, Yuri Miura2, Masafumi Ito5, Kosuke Mizutani6,7. 1. Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan. 2. Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. 3. Research Team for Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. 4. Department of Urology, Asahi University Hospital, Gifu, Japan. 5. Research Team for Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; mizutech@gifu-u.ac.jp mito@tmig.or.jp. 6. Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan; mizutech@gifu-u.ac.jp mito@tmig.or.jp. 7. Clinical Genetics Center, Gifu University Hospital, Gifu, Japan.
Abstract
AIM: To identify novel diagnostic markers for renal cell carcinoma (RCC), we analyzed miRNAs in serum extracellular vesicles (EVs). MATERIALS AND METHODS: EVs were purified from serum of healthy controls and patients with localized and advanced RCC using T-cell immunoglobulin domain and mucin domain-containing protein 4 conjugated to magnetic beads. miRNA profiling of EVs was conducted by microarray analysis. miRNA expression was examined by quantitative reverse transcription-polymerase chain reaction. Lastly, proteomic analysis of RCC cells transfected with a miRNA inhibitor was performed to identify its potential targets. RESULTS: Microarray analysis revealed that nine miRNAs were increased by more than 1.5-fold in EVs from patients with RCC. Among them, miRNA-4525 was significantly elevated; miRNA-4525 expression was higher in RCC tissue than in the adjacent normal tissue. Proteomic analysis identified alpha fetoprotein and albumin as its potential targets. CONCLUSION: These findings suggest the potential of miRNA-4525 in serum EVs as a novel biomarker for advanced RCC. Copyright
AIM: To identify novel diagnostic markers for renal cell carcinoma (RCC), we analyzed miRNAs in serum extracellular vesicles (EVs). MATERIALS AND METHODS: EVs were purified from serum of healthy controls and patients with localized and advanced RCC using T-cell immunoglobulin domain and mucin domain-containing protein 4 conjugated to magnetic beads. miRNA profiling of EVs was conducted by microarray analysis. miRNA expression was examined by quantitative reverse transcription-polymerase chain reaction. Lastly, proteomic analysis of RCC cells transfected with a miRNA inhibitor was performed to identify its potential targets. RESULTS: Microarray analysis revealed that nine miRNAs were increased by more than 1.5-fold in EVs from patients with RCC. Among them, miRNA-4525 was significantly elevated; miRNA-4525 expression was higher in RCC tissue than in the adjacent normal tissue. Proteomic analysis identified alpha fetoprotein and albumin as its potential targets. CONCLUSION: These findings suggest the potential of miRNA-4525 in serum EVs as a novel biomarker for advanced RCC. Copyright
Authors: Elena Arance; Viviana Ramírez; Alejandro Rubio-Roldan; Francisco M Ocaña-Peinado; Catalina Romero-Cachinero; Ana Belén Jódar-Reyes; Fernando Vazquez-Alonso; Luis Javier Martinez-Gonzalez; Maria Jesus Alvarez-Cubero Journal: Cancers (Basel) Date: 2021-12-31 Impact factor: 6.639